1) Discovery of protein-based biomarkers using targeted proteomics. The Stoyanova Lab utilizes multiplexed immunoassay or proximity extension assay to identify new specific biomarkers for cancer.
2) Discovery of protein-based biomarkers by proteomic profiling. The Stoyanova Lab is interested in the discovery and development of new tissue, blood, and urine-based biomarkers for clinically significant prostate cancer and other epithelial cancers.
3) The goal is to improve early cancer diagnosis and prognosis as well as to predict and monitor treatment responses to cancer therapies.